Zachodniopomorski Uniwersytet Technologiczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zachodniopomorski Uniwersytet Technologiczny W SzczeciniefiledCriticalZachodniopomorski Uniwersytet Technologiczny W Szczecinie
Priority to PL400037ApriorityCriticalpatent/PL220511B1/pl
Publication of PL400037A1publicationCriticalpatent/PL400037A1/pl
Publication of PL220511B1publicationCriticalpatent/PL220511B1/pl
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
Y02P20/00—Technologies relating to chemical industry
Y02P20/50—Improvements relating to the production of bulk chemicals
Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
Catalysts
(AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof
(AREA)
Abstract
Sposób fotokatalitycznej redukcji ditlenku wegla do metanolu, polega na jego redukcji w wodzie w obecnosci fotokatalizatora, w temperaturze 20-30°C, pod cisnieniem od 0,1 do 15 MPa i charakteryzuje sie tym, ze jako fotokatalizator stosuje sie nanorurki ditlenku tytanu.
PL400037A2012-07-192012-07-19Sposób fotokatalitycznej redukcji ditlenku węgla do metanolu
PL220511B1
(pl)
A sterile liquid formulation having an absolute viscosity of 10 cp or less, a method for reducing the viscosity of a protein formulation, and using the formulation in an amount effective for treatment
Compuestos derivados de alquil-piperazino-fenil 4(3h)ona; composicion farmaceutica y su uso para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a, tales como depresion, ansiedad, y trastornos del sueño.